Blog Detail

FDA Approves Ketamine Nasal Spray for Suicidal Thoughts and Severe Depression
46 Blogs

Renee Fabian for The Mighty – March 2019

On Tuesday, the U.S. Food and Drug Administration (FDA) approved the ketamine-based nasal spray esketamine (brand name Spravato) for treating severe persistent suicidal thoughts. The drug, which was developed by Janssen Research & Development, is the first major Esketamine — a “chemical cousin” to ketamine — works on the brain similarly to existing antidepressants. Instead of taking weeks to have an effect however, ketamine-based drugs have been shown to work almost immediately, which provides much faster relief for those with severe depression.

<a class="autolink" data-cke-saved-href="https://themighty.com/mental-health/" href="https://themighty.com/mental-health/" style="box-sizing: border-box; text-decoration-line: none; line-height: inherit; font-family: roboto, " helvetica="" neue",="" helvetica,="" arial,="" sans-serif;="" font-weight:="" 700;="" background-repeat:="" repeat-x;="" background-position:="" 100%="" 100%;="" padding-bottom:="" 1px;="" color:="" rgb(0,="" 0,="" 0)="" !important;="" background-image:="" url("https:="" themighty.com="" wp-content="" themes="" themighty="" img="" xunderline.png,qv="1.pagespeed.ic.PrejPwItKJ.webp&quot;)" !important;"="" target="_blank" title="View more mental health stories">Continue reading at this link.

Share on :